Table 2.
NGS Results Detected Before and After Treatment with Pyrotinib and Capecitabine
| Genes | 20180820 Before Pyrotinib with Capecitabine |
20181212 After Pyrotinib with Capecitabine |
Methodology | ||||
|---|---|---|---|---|---|---|---|
| Variations | Abundance | CN | Variations | Abundance | CN | ||
| HER2 | p.R157W | 2.0% | p.R157W | 1.3% | NGS | ||
| CNG | 7.7 | CNG | 2.1 | NGS | |||
| TP53 | p.L257R | 49.9% | p.L257R | 5.7% | NGS | ||
| ESR1 | Negative | Negative | NGS | ||||
| BRCA1 | Negative | Negative | NGS | ||||
| BRCA2 | Negative | Negative | NGS | ||||
Abbreviations: HER2, human epidermal growth factor receptor-2; TP53, tumor protein p53; ESR1, estrogen receptor 1; BRCA1, breast cancer susceptibility gene 1; BRCA2, breast cancer susceptibility gene 2; CNG, copy number gain; CN, copy number; NGS, next-generation sequencing.